Australian Government Accused of Misusing Funds to Combat E-Cigarettes

Sep.09.2022
Australian Government Accused of Misusing Funds to Combat E-Cigarettes
CAPHRA Coordinator Nancy Loucas criticizes Australian government's anti-vaping campaign as a misuse of public funds.

Nancy Loucas, the executive coordinator of the Asia Pacific Advocates for Tobacco Harm Reduction (CAPHRA), has expressed that the crackdown on e-cigarette retailers in Australia constitutes a serious misuse of public funds, which should be directed towards improving the country's healthcare system.


Before she issued her statement, the government of New South Wales in Australia intensified its warnings to compliant retailers about the risks associated with e-cigarette products. They also continue to back a controversial joint "education campaign" with the Department of Education on the issue of e-cigarettes.


The centerpiece of the event is the "Get the Facts" - Vaping Toolkit aimed at teachers, parents, and adolescent students. CAPHRA stated that despite Deputy Chief Health Officer Dr. Marianne Gale's assurance that the website does not contain "evidence-based resources and educational materials," it should be taken down while its many statements are independently verified.


These claims about electronic cigarettes are either completely exaggerated or, in the worst case scenario, have no scientific basis. The Australian public, regardless of age, needs to have complete confidence in any health statements on government websites. Unfortunately, this campaign is far from factual. Instead, it is filled with blatant lies," said Ms. Lucas.


In a statement that has angered advocates for tobacco harm reduction (THR) throughout the entire Asia-Pacific region, Dr. Gale claimed, "Many people believe that e-cigarettes are either completely harmless or less harmful than traditional cigarettes.


In a recent situation, an Australian chief health officer has been actively informing the public that the harm of vaping is not less than smoking. However, international research strongly refutes this claim. Despite providing no evidence to support her statement, the Australian public continues to receive such costly yet worthless advice. This is a complete embarrassment," she said.


According to CAPHRA, Australians who want to know the truth about vaping should look to New Zealand. Adults can legally use nicotine e-cigarettes there under regulations targeting retailers and manufacturers in 2020. Smokers looking to quit do not need to obtain a prescription from a doctor, unlike in Australia.


Asking doctors to prescribe cigarettes has left 2.3 million smokers in Australia disappointed, not to mention the approximately 20,000 Australians who die each year from smoking-related illnesses. While Australia's overall smoking rate has remained stagnant over the past decade, New Zealand has seen a 50% decrease in its smoking rate, largely due to the availability of legally sanctioned, less harmful alternatives for smokers, according to Ms. Lucas.


CAPHRA has pointed out that the headline of the New Zealand Ministry of Health's "Vaping facts" website states that "vaping is less harmful than smoking".


New Zealand is engaging in a positive dialogue with the public with the goal of achieving a smoke-free nation by 2025, with a smoking rate of 5% or less. In contrast, health leaders in Australia are continuing to ban adults from entering retail stores while using significant public resources to deter the use of e-cigarettes.


Australia's healthcare system is failing miserably. The persistent threats and lies surrounding e-cigarettes will make it almost impossible to achieve the country's goal of reducing smoking rates by 10% in the short term. They need a new strategy to eradicate tobacco, as the current one clearly isn't working," said Nancy Lucas.


CAPHRA, an advocacy group, has amassed almost 15,000 endorsement letters and is urging those who have quit smoking through the use of nicotine-free alternatives to share their stories on www.righttovape.org.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the opinion of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article’s content. The compilation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14